FDA Approves New Roche Drug Uses for Cancer, Kidney and Eye Diseases
Photo: TokenPost
The U.S. Food and Drug Administration (FDA) approved new uses for Roche medicines in kidney disease, colon cancer and thyroid eye disease, with decisions spanning Sept. 25 to Oct. 15. On Oct. 8, the FDA cleared Tecentriq with fluoropyrimidine and oxaliplatin as an adjuvant regimen for patients at least 2 years old with stage III colon cancer and mismatch repair deficiency. The agency also approved Tecentriq Hybreza with the same chemotherapy for patients ages 12 and older who weigh at least 40 kilograms.
Source: TokenPost
